85 completed, 22 unknown, 12 recruiting, 10 terminated. 40 Not applicable, 31 Phase 2, 30 Phase 4, 16 Phase 3, 1 Early Phase 1.
Follow Albuminuria: new trials by email Literature Review of Albuminuria trials Research Report on Albuminuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relationship Between Insulin Dose and Complications in Type 1 Diabetes Routine/prescribed exogenous insulin dose - Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD) | Not yet recruiting | Rachel Miller | 80 | 2027-01-01 | 2026-11-02 | |
| Obesity-Related Indices and Albuminuria in Type 2 Diabetes Obesity and Diabetes Mellitus, Type 2, Albuminuria | Not yet recruiting | Assiut University | 349 | 2026-11-10 | 2026-11-06 | |
| Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria Electronic Health Record alert - Referral and Consultation, Glomerulonephritis | Not applicable | Recruiting | Geisinger Clinic | 1200 | 2026-11-01 | 2026-11-12 |
| Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria Finerenone, Finerenone Placebo, Semaglutide - Obesity; Chronic Kidney Disease; Albuminuria | Not applicable | Not yet recruiting | Peking University People's Hospital | 266 | 2026-09-01 | 2026-09-30 |
| Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease Diabetic Kidney Disease, Diabetic Nephropathies | Not yet recruiting | Assiut University | 120 | 2026-09-01 | 2026-08-19 | |
| RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM) Epic-Based Clinician Notification, Usual Care - Chronic Kidney Disease, Type 2 Diabetes | Not applicable | Enrolling by invitation | Baylor Research Institute | 600 | 2026-08-06 | 2026-10-15 |
| Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease Finerenone (BAY 94-8862), Placebo - Albuminuria, Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 148 | 2026-07-01 | 2026-06-25 |
| Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease Human Wharton's jelly mesenchymal stem cell (HWJ-MSC) exosomes, Human umbilical vein endothelial cell (HUVEC) exosomes, Placebo (0.9% sodium chloride) - Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4 | Phase 1 / Phase 2 | Completed | Nurhasan Agung Prabowo | 34 | 2026-07-01 | 2026-11-06 |
| Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease Dapagliflozin (10mg Tab), Placebo - Chronic Kidney Disease (Mild to Moderate), Albuminuria | Phase 4 | Recruiting | Centenario Hospital Miguel Hidalgo | 200 | 2026-04-23 | 2026-04-27 |
| Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin Empagliflozin (oral) - Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Recruiting | University of Illinois at Chicago | 20 | 2026-04-08 | 2026-05-19 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors Finerenone (BAY 94-8862), Placebo - Chronic Kidney Disease | Phase 3 | Enrolling by invitation | University Medical Center Groningen | 180 | 2026-03-13 | 2026-04-14 |
| Rubix LS Diabetic Kidney Disease (DKD) Registry Study Kidney-Protective Therapies Used in Routine Care - Diabetic Kidney Disease (DKD) | Active not recruiting | Rubix LS | 2000 | 2025-12-15 | 2026-01-16 | |
| Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA) - Type 2 DM, Type 2 DM /Diabetic Nephropathy | Phase 4 | Enrolling by invitation | Steno Diabetes Center Copenhagen | 50 | 2025-11-20 | 2025-12-22 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease Autosomal Dominant Polycystic Kidney Disease (ADPKD | Recruiting | King's College London | 200 | 2025-08-15 | 2026-11-04 | |
| Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome Spirulina Arthrospira platensis (microalgae), Gelidium corneum, Placebo - Stroke, Coronary Arterial Disease (CAD) | Not applicable | Recruiting | Universidade do Porto | 150 | 2025-03-11 | 2025-09-15 |
| Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia Sotagliflozin, Placebo - Nephropathy, Diabetic Nephropathies | Phase 2 | Not yet recruiting | Steno Diabetes Center Copenhagen | 69 | 2025-02-01 | 2025-01-27 |
| The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin - Acute Kidney Injury | Phase 2 | Recruiting | National Taiwan University Hospital | 264 | 2024-11-21 | 2026-01-02 |
| Effect Camostat for Kidney Protection in Chronic Kidney Disease Camostat Mesylate - Chronic Kidney Disease(CKD) | Phase 2 | Recruiting | Odense University Hospital | 40 | 2024-11-21 | 2025-01-27 |
Showing 20 of 142. Sign in to see all of them.
Renal Insufficiency, Chronic (45) · Diabetic Nephropathies (38) · Diabetes Mellitus, Type 2 (37) · Hypertension (33) · Diabetes Mellitus (26) · Proteinuria (21) · Kidney Diseases (16) · Cardiovascular Diseases (10) · Diabetes Mellitus, Type 1 (7) · Anemia, Sickle Cell (6) · Diabetes Complications (5) · Obesity (5) · Renal Insufficiency (5) · Acute Kidney Injury (3)
Female Urogenital Diseases (142) · Female Urogenital Diseases and Pregnancy Complications (142) · Male Urogenital Diseases (142) · Pathological Conditions, Signs and Symptoms (142) · Signs and Symptoms (142) · Urination Disorders (142) · Urogenital Diseases (142) · Urologic Diseases (142) · Urological Manifestations (142) · Proteinuria (121) · Endocrine System Diseases (78) · Kidney Diseases (78) · Nutritional and Metabolic Diseases (73) · Metabolic Diseases (69) · Glucose Metabolism Disorders (64)
dapagliflozin (9) · finerenone (7) · empagliflozin (6) · Valsartan (5) · Lisinopril (4) · Losartan (4) · aliskiren (4) · semaglutide (4) · Canagliflozin (3) · Diet, Sodium-Restricted (3) · Hydrochlorothiazide (3) · Ramipril (3) · Spironolactone (3) · benazepril (3) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (2)
University Medical Center Groningen (7) · Geisinger Clinic (5) · Steno Diabetes Center Copenhagen (5) · Novartis (4) · Medical University of Gdansk (3) · Assiut University (2) · AstraZeneca (2) · Baylor Research Institute (2) · Donald Wesson (2) · Healthy.io Ltd. (2) · Icahn School of Medicine at Mount Sinai (2) · Istanbul University (2) · Keryx Biopharmaceuticals (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Peter Rossing (2)
United States (50) · Netherlands (13) · Denmark (12) · Spain (10) · Canada (9) · Australia (8) · Germany (8) · Italy (8) · Poland (8) · France (7) · South Korea (7) · United Kingdom (7) · China (6) · Japan (5) · Mexico (5)
Ian H de Boer, MD, MS (2) · Mary Ann McLaughlin, MD, MPH (2) · Mohammad G. Saklayen, MD (2) · Rajiv Saran, MD (2) · Abdullah Ozkok, MD (1) · Alaattin Yildiz, Professor of Medicine, MD (1) · Alessandro Flavio Ferri (1) · Alex Chang, MD (1) · Alex Chang, MD, MS (1) · Alex R Chang, MD (1) · Alex R Chang, MD, MS (1) · Alexander Arutyunov, professor (1) · Amy Mottl, MD, MPH (1)
PMID 33107592, PMID 34164803, PMID 41805697, PMID 38682786, PMID 38770818, PMID 17488800, PMID 17667984, PMID 18382267, PMID 18443191, PMID 18716365, PMID 18974967, PMID 19141364, PMID 19850697, PMID 21243736, PMID 21441399, PMID 21872376, PMID 22113127, PMID 22338101, PMID 22773704, PMID 22784975, PMID 23013602, PMID 23020932, PMID 23093684, PMID 23491522, PMID 23565931, PMID 23615312, PMID 23732715, PMID 23733198, PMID 23741057, PMID 23829205, PMID 23929932, PMID 24366425, PMID 24624891, PMID 24798861, PMID 25531146, PMID 25887073, PMID 25942403, PMID 26098847, PMID 26155957, PMID 26390102, PMID 27019421, PMID 27206819, PMID 27222591, PMID 27487357, PMID 28605608, PMID 29133604, PMID 29310645, PMID 29526832, PMID 29574497, PMID 29693360
1KL2RR025015-01 (1), 2015 (1), 2018 (1), 2023 (1), 2025 (1), K23HL148394 (1), P20GM109036 (1), P30DK017047 (1), R01DK088762 (1), R01HL111659 (1), R01HL159376 (1), R21AT002367 (1), R34DK094016 (1), U01DK112271 (1), U01MD010550 (1)